780 BRANNAN STREET, SAN FRANCISCO, CA
Investor Presentation
Announces New Clinical Trial Agreement to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer
Reports Second Quarter 2025 Financial and Operating Results
Shareholder votes
Earnings Release
Annual Report to Security Holders
Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Correspondence